The rationale for this study is to observe the effect of a consumer-grade commercially available product called Mimio Biomimetic Cell Care on metabolic health in overweight individuals. Additionally, the study aims to observe the effects of the study product on hunger and satiety, as well as effects on cognitive function, sleep, stress, pain, mood, gastrointestinal symptoms and metabolic and inflammatory blood markers via activities that can successfully and effectively be completed in a home setting. Because this product is currently available in the OTC market across the United States, a consumer-driven, decentralized observational clinical research study is well-suited for examining the effects of this study product in this population.

The study will examine outcomes in a broad age range of adults who have chosen to try this product. The study will incorporate participant reported outcome questionnaires and surveys, blood sample collection for NMR lipoprofile, oxidized LDL, hsCRP, HbA1c, Insulin and plasma glucose and a saliva sample collection for biological age test. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to take the product and take part in the observational process with self-reported measures, saliva sample collection and blood sample collection at their local laboratory. Findings from this study will contribute knowledge toward the design of future studies and important knowledge on metabolic health.

Intermittent fasting has gained significant scientific and clinical interest in recent years due to its well documented beneficial effects on a wide range of health conditions including cardiovascular disease, metabolic disorders, neurodegenerative conditions, cancer, and autoimmune disease in both clinical and experimental settings. Moreover, prolonged periods of fasting remain one of the only reliable methods of extending lifespan in model organisms due to its reported ability to modulate the cellular aging process. Despite fasting's potential to significantly improve human health by helping to treat, prevent, or delay disease and enhance overall longevity, the prolonged timescale of fasting required to achieve such benefits (typically greater than 24 hrs) is often infeasible or dangerous for numerous populations and adds significant burdens to quality of life which prevent fasting's widespread adoption. Interventions capable of mimicking the beneficial cellular, metabolic, immune, and longevity enhancing effects of fasting without the need to abstain from food, hold great potential therapeutic value for both the treatment and prevention of chronic health conditions especially for those for whom fasting may be contraindicated.

Spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide (OEA) are endogenous human metabolites that have been shown to have numerous beneficial effects, including improved clinical markers of disease, extended lifespan, and both anti-inflammatory and antioxidant properties. A previous study conducted by the Mimio Health group identified higher plasma concentrations of these metabolites after a 36 hour fast compared to a 12-hour overnight fast and demonstrated that a combination of spermidine, 1-methlynicotinamide (1-MNA): a cellular derivative of nicotinamide, PEA, and OEA could mimic many of the functional benefits of prolonged fasting including significant anti-inflammatory and antioxidant effects in vitro and extending lifespan in C. elegans. The study team has also shown in a pilot clinical study that the combination of spermidine, PEA, OEA, and nicotinamide when taken as a supplement is orally bioavailable, well-tolerated, and capable of replicating similar anti-inflammatory, antioxidant, and cardioprotective effects as fasting even when taken in the postprandial state. The goal of this study is to confirm the beneficial effects of this novel fasting mimetic formulation (Mimio Biomimetic Cell Care) and further explore its potential therapeutic value on metabolic health and longevity in a randomized, double-blind, placebo controlled study.

Inclusion Criteria:

• Age 55 years old and above
• Have a BMI between 25 to 29.9 from self-reported weight and height measured within the last 6 months prior to randomization
• Interested in understanding more about their metabolic health
• If taking any prescription medication for cholesterol (e.g. statins) or other class of medications for metabolic disorders such as metformin, ACE inhibitors, beta blockers, rapamycin, thiazolidinediones, etc., must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study
• If taking any fiber supplements, must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study. If not on a stable dose, must be willing to stop at least 1 week prior to randomization and throughout the course of the study.
• If taking any other supplement products such as fish oil, resveratrol, alpha-ketoglutarate, berberine, ashwagandha, pre- and probiotics, melatonin, NAD+ precursors (niacin, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), NADH, etc), fisetin, astaxanthin, urolithin-A, CoQ-10, green tea extract or EGG, pterostilbene, must be willing to stop at least 1 week prior to randomization and throughout the course of the study
• If using any cannabis, THC, or CBD containing products regularly, must be willing to stop at least 1 week prior to randomization and throughout the course of the study
• Must be on a consistent and regular diet for at least 2 months prior to randomization and willing to maintain it throughout the course of the study
• For females, must be in menopausal stage
• In good general health at the time of screening (Investigator discretion).
• Able to read and understand English.
• Able to read, understand, and provide informed consent.
• Able to use a personal smartphone device and download Chloe by People Science.
• Able to receive shipment of the product at an address within the United States.
• Able and willing to travel to a local Quest Diagnostics laboratory for blood sample collection (with fasting) twice during the course of the study
• Able to complete study assessments over the course of up to 10 weeks.

Exclusion Criteria:

-Do not have a personal smartphone, internet access, or unwilling to download Chloe.

Concomitant Therapies:

• GLP-1 receptor agonists and related incretin mimetics, (e.g. semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), sitagliptin (Januvia, Janumet), saxagliptin (Onglyza, Komblglyze), alogliptin (Nesina, Kazano, Oseni), linagliptin (Tradjenta, Jentadueto) or tirzepatide (Mounjaro))
• Hormone Replacement Therapy (especially fluctuating/ cycle mimicking dose) or Hormonal Contraceptives (oral or IUD)
• Participants receiving any investigational therapies or treatments within 30 days prior to randomization.
• Concurrent participation in any other investigational study during the study period.
• Regular use of over-the-counter allergy or pain medications (including ibuprofen, acetaminophen, aspirin, naproxen, diphenhydramine, cetirizine, loratadine, fexofenadine ) (>3-4 times/week).

Other Illnesses or Conditions: Participants who have the following comorbidities or conditions are excluded:

• Currently or previously diagnosed with Obesity (BMI greater than 29.9)
• Known diagnosis of Type 1 or Type 2 Diabetes Mellitus requiring medical intervention.
• Known diagnosis of an eating disorder
• Currently diagnosed with Alcohol Abuse and/or Substance Use Disorder
• Women not yet in menopause (Have had a menstrual period within the last 12 months)
• Currently diagnosed with Anemia
• Significant cardiovascular disease or severe cardiac event, except hypertension.
• Current or past diagnosis with cancer of any kind, except non-melanoma skin cancer
• Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes.
• Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
• Have undergone a major change in diet or on a special diet (e.g. intermittent fasting, carnivore diet, keto diet, vegan/vegetarian, extending fasting etc.) 60 days prior to enrollment or who initiated such a change at any time during the study.
• Recent weight fluctuations (greater than 10% in the last six months)
• Smoker or use of tobacco or nicotine products.
• Regular use of any cannabis, THC, or CBD containing products or unwillingness to cease use of such products 1 week prior to randomization and throughout the duration of the study period.
• Alcohol use exceeding 14 units/week or unwillingness to change drinking habits to 14 or less units/week 1 week prior to randomization and throughout the duration of the study period
• Known hypersensitivity or previous allergic reaction to nicotinamide, palmitoylethanolamide, oleoylethanolamide, spermidine
• Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

Healthy participants who meet the eligibility criteria will be recruited through People Science community, email outreach, advocacy groups and social media channels. Advertisements will be in paper and digital format and will link to a study landing page to enable sign up.